Fulgent Genetics (MEX:FLGT) Retained Earnings : MXN11,194 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Fulgent Genetics's retained earnings for the quarter that ended in Jun. 2024 was MXN11,194 Mil.

Fulgent Genetics's quarterly retained earnings declined from Dec. 2023 (MXN10,748 Mil) to Mar. 2024 (MXN10,285 Mil) but then increased from Mar. 2024 (MXN10,285 Mil) to Jun. 2024 (MXN11,194 Mil).

Fulgent Genetics's annual retained earnings increased from Dec. 2021 (MXN13,490 Mil) to Dec. 2022 (MXN15,616 Mil) but then declined from Dec. 2022 (MXN15,616 Mil) to Dec. 2023 (MXN10,748 Mil).

Fulgent Genetics Retained Earnings Historical Data

The historical data trend for Fulgent Genetics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Retained Earnings Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-1,196.27

3,001.33

13,489.95

15,616.30

10,747.67

Fulgent Genetics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Retained Earnings	Get a 7-Day Free Trial															13,276.77	13,261.42	10,747.67	10,284.92	11,193.64

Fulgent Genetics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Fulgent Genetics (MEX:FLGT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.